Kentucky Retirement Systems decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 1.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,385 shares of the company’s stock after selling 481 shares during the quarter. Kentucky Retirement Systems’ holdings in Zoetis were worth $5,961,000 as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of ZTS. Webster Bank N. A. lifted its holdings in Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in shares of Zoetis in the fourth quarter worth $40,000. LRI Investments LLC bought a new stake in shares of Zoetis during the 1st quarter worth $43,000. Ables Iannone Moore & Associates Inc. bought a new stake in shares of Zoetis during the 4th quarter worth $51,000. Finally, Hazlett Burt & Watson Inc. grew its stake in Zoetis by 60.7% in the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after buying an additional 102 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.
Zoetis Stock Performance
NYSE:ZTS opened at $193.24 on Friday. The stock has a market capitalization of $88.17 billion, a P/E ratio of 37.23, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a 50 day moving average of $184.42 and a 200-day moving average of $174.44.
Analysts Set New Price Targets
A number of research firms have weighed in on ZTS. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Stifel Nicolaus increased their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday. Piper Sandler lifted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $220.38.
Get Our Latest Stock Report on ZTS
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Stories
- Five stocks we like better than Zoetis
- The Basics of Support and Resistance
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- The How And Why of Investing in Oil Stocks
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What is a SEC Filing?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.